PCI Biotech Holding ASA (PCIB.OL)
| Previous Close | 1.6800 |
| Open | 1.6600 |
| Bid | 1.5300 x 20000 |
| Ask | 1.9000 x 12500 |
| Day's Range | 1.6500 - 1.7760 |
| 52 Week Range | 1.2000 - 3.4000 |
| Volume | |
| Avg. Volume | 88,597 |
| Market Cap | 61.589M |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7900 |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswirePCI Biotech second half 2023 interim results
Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review OperationsThe use of fimaNAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing. The most recently reported 2023 milestone was i
- GlobeNewswire
PCI Biotech: Invitation to second half interim 2023 results presentation
Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time). The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim rep
- GlobeNewswire
PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today announced a research collaboration agreement with the aim to address critical pain points in the manufacturing of gene therapies. The partners have signed a collaborative research agreement with the purpose of testing PCI Biotech’s proprietary technology for gene therapy manufacturing in the partners’ pilot manufacturing process. PCI Biotech brings its novel and promising technology for viral vector manufacturing into the field testin
